EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Efficacy of N-Acetylcysteine on Liver Function and Metabolic Profiles in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Double-Blind, Randomized Controlled Trial

Mehrdad Sinaeinejad, Mehdi Karimi iD, Mohsen Razavizadeh, Abbas Arj, Seyyed Hamed Tabatabaei, Masoud Mortezazadeh iD, Niyousha Shirsalimi iD, Samira Pirzad iD, Abbas Mofidi, Mehdi Kashani

Addiction and Health · 03.11.2025 · 17 · 1667

DOI: 10.34172/ahj.1667 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Addiction and Health, online erschienen am 03.11.2025. Verfasst von Mehrdad Sinaeinejad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), is a common liver disorder associated with metabolic abnormalities. This study aimed to evaluate the effectiveness of N-acetylcysteine (NAC) in improving liver function and metabolic profile in patients with MASLD.

Methods

In this randomized controlled trial (RCT), 69 patients with MASLD were randomly assigned to either the NAC group (600 mg, administered three times daily, n=34) or the placebo group (n=35) for eight weeks. The severity of hepatic steatosis, liver enzymes, and metabolic profile were measured at baseline and the final trial. Data were analyzed using SPSS.

Findings

Following eight weeks of NAC administration in patients with MASLD, no significant changes were observed compared to the placebo in hepatic steatosis grade (P=0.215), serum aspartate aminotransferase (AST) (P=0.21), alanine transaminase (ALT) (P=0.28), malondialdehyde (MDA) (P=0.79), total antioxidant capacity (TAC) (P=0.56), triglycerides (P=0.15), total cholesterol (P=0.28), low-density lipoprotein cholesterol (P=0.32), and high-density lipoprotein cholesterol (P=0.16). However, NAC administration resulted in significant reductions in fasting blood glucose (FBG) (P=0.01), fasting insulin levels (P

Schlagwörter

Stichwörter der Autor:innen

Clinical trialFatty liver diseaseHepatic steatosisMetabolic dysfunctionMetabolic profileN-acetylcysteine

Autor:innen und Institutionen

  • Department of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran.
  • Faculty of Medicine, Bogomolets National Medical University (NMU), Kyiv, Ukraine.
  • Department of Hematology-Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
  • Faculty of Medicine, Hamadan University of Medical Sciences (UMSHA), Hamadan, Iran.
  • Faculty of Medicine, Islamic Azad University, Tehran Medical Sciences Branch (IAUTMU), Tehran, Iran.
  • School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.

ORCID-Profile: Mehdi Karimi, Masoud Mortezazadeh, Niyousha Shirsalimi, Samira Pirzad

Zitieren

APA

Sinaeinejad, M., Karimi, M., Razavizadeh, M., Arj, A., Tabatabaei, S. H., Mortezazadeh, M., Shirsalimi, N., Pirzad, S., Mofidi, A., & Kashani, M. (2025). Efficacy of N-Acetylcysteine on Liver Function and Metabolic Profiles in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Double-Blind, Randomized Controlled Trial. Addiction and Health, 17, 1667. https://doi.org/10.34172/ahj.1667

Vancouver

Sinaeinejad M, Karimi M, Razavizadeh M, Arj A, Tabatabaei SH, Mortezazadeh M, et al. Efficacy of N-Acetylcysteine on Liver Function and Metabolic Profiles in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Double-Blind, Randomized Controlled Trial. Addiction and Health. 2025;17:1667. doi:10.34172/ahj.1667

BibTeX
@article{Sinaeinejad2025,
  author = {Sinaeinejad, Mehrdad and Karimi, Mehdi and Razavizadeh, Mohsen and Arj, Abbas and Tabatabaei, Seyyed Hamed and Mortezazadeh, Masoud and Shirsalimi, Niyousha and Pirzad, Samira and Mofidi, Abbas and Kashani, Mehdi},
  title = {Efficacy of N-Acetylcysteine on Liver Function and Metabolic Profiles in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Double-Blind, Randomized Controlled Trial},
  journal = {Addiction and Health},
  year = {2025},
  volume = {17},
  pages = {1667},
  doi = {10.34172/ahj.1667}
}
Kostenlos starten →